184 related articles for article (PubMed ID: 26546142)
1. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Coleman CI; Freemantle N; Kohn CG
BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Kohn CG; Parker MW; Limone BL; Coleman CI
Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Nguyen E; Coleman CI; Kohn CG; Weeda ER
Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
[TBL] [Abstract][Full Text] [Related]
5. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
8. Impact of angina frequency on health utility values of patients with chronic stable angina.
Kohn CG; Parker MW; Limone BL; Coleman CI
Health Qual Life Outcomes; 2014 Mar; 12():39. PubMed ID: 24628859
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
Ayyasamy L; Bagepally BS
Clin Ther; 2023 May; 45(5):458-465. PubMed ID: 37087299
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine reduces patient-reported angina severity and frequency and improves quality of life in selected patients with chronic angina.
Muhlestein JB; Grehan S
Drugs R D; 2013 Sep; 13(3):207-13. PubMed ID: 23990357
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine: A Contemporary Review.
Rayner-Hartley E; Sedlak T
J Am Heart Assoc; 2016 Mar; 5(3):e003196. PubMed ID: 26979079
[No Abstract] [Full Text] [Related]
13. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic management of chronic stable angina.
Dixit D; Kimborowicz K
JAAPA; 2015 Jun; 28(6):. PubMed ID: 25989429
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
Rosano GMC; Vitale C; Volterrani M
Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
[TBL] [Abstract][Full Text] [Related]
17. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine for Symptomatic Management of Microvascular Angina.
Rayner-Hartley E; Parvand M; Humphries KH; Starovoytov A; Park JE; Sedlak T
Am J Ther; 2020; 27(2):e151-e158. PubMed ID: 29746286
[TBL] [Abstract][Full Text] [Related]
19. Update on ranolazine in the management of angina.
Codolosa JN; Acharjee S; Figueredo VM
Vasc Health Risk Manag; 2014; 10():353-62. PubMed ID: 25028555
[TBL] [Abstract][Full Text] [Related]
20. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
